Nilgün Çakar

Nilgün Çakar

Auto-generated profile, based on publicly available information

Nilgün Çakar

Division of Pediatric Rheumatology, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2009 in Rheumatology
Verified
Journal Article
Open access
PDF file
FYFatoş Yalçınkaya
Fatoş Yalçınkaya
SÖSeza Özen
Seza Özen
ZÖZeynep Birsin Özçakar
Zeynep Birsin Özçakar
NANuray Aktay
Nuray Aktay
NÇNilgün Çakar
Nilgün Çakar
ABAyşin Bakkaloğlu
Ayşin Bakkaloğlu
Objectives. Several sets of criteria mainly for adults have been proposed for the diagnosis of FMF. The aim of the present study is to validate the most widely used diagnostic ‘Tel Hashomer’ criteria in children and to establish a new set of criteria for use in childhood. Methods. The study group consisted of 170 recently diagnosed FMF patients who had mutations at both alleles. They were interviewed about the presence of 35 features and manifestations of FMF at the time of diagnosis. Controls were consecutive patients without FMF (n = 141) who had episodes of fever and clinical features mimicking that of FMF. The diagnostic performance of the candidate features was assessed by multiple logistic regression analysis. Results. The sensitivity and specificity of Tel Hashomer criteria in our study group were 98.8 and 54.6%, respectively. The multiple logistic regression analysis showed that 5 (fever, abdominal pain, chest pain, arthritis and family history of FMF) of the 35 candidate criteria discriminate FMF from controls with a sensitivity and specificity of 88.8 and 92.2%, respectively. The presence of two or more of these five criteria diagnosed FMF with a sensitivity of 86.5% and a specificity of 93.6%. Conclusion. It was demonstrated that although the Tel Hashomer criteria were successful in diagnosing the FMF patients in childhood, its specificity was definitely low in children. The new set of criteria has a high sensitivity and specificity for the diagnosis of FMF and is practical to use on an everyday basis.

1 April 2015 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ATAgnes Trautmann
Agnes Trautmann
MBMonica Bodria
Monica Bodria
FOFatih Ozaltin
Fatih Ozaltin
AGAlaleh Gheissari
Alaleh Gheissari
AMAnette Melk
Anette Melk
FSFranz Schaefer
Franz Schaefer
Background and objectives Steroid-resistant nephrotic syndrome is a rare kidney disease involving either immune-mediated or genetic alterations of podocyte structure and function. The rare nature, heterogeneity, and slow evolution of the disorder are major obstacles to systematic genotype-phenotype, intervention, and outcome studies, hampering the development of evidence-based diagnostic and therapeutic concepts. To overcome these limitations, the PodoNet Consortium has created an international registry for congenital nephrotic syndrome and childhood-onset steroid-resistant nephrotic syndrome. Design, setting, participants, & measurements Since August of 2009, clinical, biochemical, genetic, and histopathologic information was collected both retrospectively and prospectively from 1655 patients with childhood-onset steroid-resistant nephrotic syndrome, congenital nephrotic syndrome, or persistent subnephrotic proteinuria of likely genetic origin at 67 centers in 21 countries through an online portal. Results Steroid-resistant nephrotic syndrome manifested in the first 5 years of life in 64% of the patients. Congenital nephrotic syndrome accounted for 6% of all patients. Extrarenal abnormalities were reported in 17% of patients. The most common histopathologic diagnoses were FSGS (56%), minimal change nephropathy (21%), and mesangioproliferative GN (12%). Mutation screening was performed in 1174 patients, and a genetic disease cause was identified in 23.6% of the screened patients. Among 14 genes with reported mutations, abnormalities in NPHS2 (n=138), WT1 (n=48), and NPHS1 (n=41) were most commonly identified. The proportion of patients with a genetic disease cause decreased with increasing manifestation age: from 66% in congenital nephrotic syndrome to 15%–16% in schoolchildren and adolescents. Among various intensified immunosuppressive therapy protocols, calcineurin inhibitors and rituximab yielded consistently high response rates, with 40%–45% of patients achieving complete remission. Confirmation of a genetic diagnosis but not the histopathologic disease type was strongly predictive of intensified immunosuppressive therapy responsiveness. Post-transplant disease recurrence was noted in 25.8% of patients without compared with 4.5% (n=4) of patients with a genetic diagnosis. Conclusions The PodoNet cohort may serve as a source of reference for future clinical and genetic research in this rare but significant kidney disease.

1 January 2000 in Rheumatology
Verified
Journal Article
Open access
PDF file
FYF. Yalçınkaya
F. Yalçınkaya
NÇN. Çakar
N. Çakar
MMM. Mısırlıoğlu
M. Mısırlıoğlu
NTN. Tümer
N. Tümer
NAN. Akar
N. Akar
AEAtilla Halil Elhan
Atilla Halil Elhan
Objectives. Differences in clinical manifestations of familial Mediterranean fever (FMF) between different ethnic groups have been documented. The FMF gene was recently cloned and four missense mutations (Met694Val, Met680Ile, Val726Ala, and Met694Ile) that account for a large percentage of the patients were identified. The results of initial mutation studies have led to the hypothesis that phenotypic variation of the disease may be attributable to the existence of some of these mutations. The purpose of this study was to evaluate whether this phenotypic variation is associated with the existence of particular mutations in Turkish FMF patients living in Turkey. Methods. Four missense mutations and genotype–phenotype correlation were investigated in 167 Turkish FMF patients. The patients were grouped according to the presence of the Met694Val and the Met680Ile mutations, and 12 clinical parameters were compared between the groups. Results. The presence of the Met694Val mutation was not found to be associated with a severe form of the disease or the development of amyloidosis. Arthritis frequency was found to be lower in the patients with homozygous Met680Ile mutation. Conclusions. None of the four missense mutations is associated with a severe disease or the development of amyloidosis in Turkish FMF patients living in Turkey. The influence of unknown environmental factors and/or the presence of other genetic changes are necessary to explain the phenotypic variation of the disease and the development of amyloidosis.

1 September 2007 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
ABAysun K. Bayazit
Aysun K. Bayazit
FYFatos Yalcinkaya
Fatos Yalcinkaya
NCNilgun Cakar
Nilgun Cakar
ADAli Duzova
Ali Duzova
ZBZelal Bircan
Zelal Bircan
ASAlper Soylu
Alper Soylu

9 June 1999 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
NTN. Tümer
N. Tümer
FYF. Yalçinkaya
F. Yalçinkaya
EIE. İnCe
E. İnCe
MEM. Ekim
M. Ekim
KKK. Köse
K. Köse
SÖS. Önder
S. Önder

1 July 2019 in Kidney International
Verified
Journal Article
Closed access
KAKarolis Azukaitis
Karolis Azukaitis
WJWenjun Ju
Wenjun Ju
MKMarietta Kirchner
Marietta Kirchner
VNViji Nair
Viji Nair
MSMichelle Smith
Michelle Smith
TNThomas J. Neuhaus
Thomas J. Neuhaus